Evaluation of the AMPLICOR CMV test for direct detection of cytomegalovirus in plasma specimens

Hiyoshi, M; Tagawa, Shinichi; Takubo, Takayuki; Tanaka, Kazuo; Nakao, Takafumi; Higeno, Yasuhiro; Tamura, Kenichi; Shimaoka, Masayuki; Fujii, Atuo; Higashihata, Masamitsu; Yasui, Yoshinori; Kim, Taku; Hiraoka, A; Tatsumi, Noriyuki

doi:10.1128/jcm.35.10.2692-2694.1997

Cited by 34 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, antigenemia declined faster than CMV-DNAnemia, after treatment. [10,11]. The key to evaluating the clinical utility of molecular assays for detection of CMVD is clinical correlation with the laboratory results.…”

Section: Discussionmentioning

confidence: 99%

Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients

et al. 2005

View full text Add to dashboard Cite

Summary The relationship between quantitative antigenemia and plasma DNAemia was studied for monitoring cytomegalovirus (CMV) viremia in CMV infection (CMVI) or disease (CMVD), in 20 transplant recipients (13 CMD, seven CMVI). A total of 142 samples of blood were assayed for CMV‐DNA and pp‐65 antigenemia (CMV‐Ag). A quantitative correlation between both markers was found (P < 0.0001). First CMV antigenemia as well as first plasma DNA viral load was similar in CMVI and CMVD (29 vs. 24 CMV‐Ag+ cells/105 PMN; and 7445 vs. 12407 CMV‐DNA copies/ml). The maximum antigenemia was higher in CMVD than in CMVI (146 ± 87 vs. 61 ± 54 +cells/105 PMN, P < 0.05), but the highest CMV plasma viral load was similar in both groups (62592 ± 33000 vs. 42055 ± 38600 copies/ml). In nine patients, maximum antigenemia coincided with highest plasma DNA viral load, but in 10 highest DNAemia occurred 6 days later. On the contrary, antigenemia declined faster than CMV‐DNAnemia, after treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The clinical utility of the AMPLICOR CMV Test with plasma specimens has recently been demonstrated in a study with bone marrow transplant recipients (9). That study showed that plasma PCR is more sensitive than the antigen assay at detecting CMV disease.…”

Section: Discussionmentioning

confidence: 99%

Detection of Cytomegalovirus in Plasma and Cerebrospinal Fluid Specimens from Human Immunodeficiency Virus-Infected Patients by the AMPLICOR CMV Test

et al. 1998

View full text Add to dashboard Cite

We have developed the AMPLICOR CMV Test, which is rapid and sensitive for the detection of cytomegalovirus (CMV) in plasma and cerebrospinal fluid (CSF) specimens. The test incorporated an internal control in the reaction mixture to monitor the amplification efficiency and the presence of inhibitors. The AMPLICOR CMV Test was very specific in detecting 12 clinical CMV isolates and four laboratory CMV strains tested. Cross-reactivity with 26 non-CMV pathogens was not observed. The AMPLICOR CMV Test requires only 50 μl of specimen (plasma or CSF) for processing. The performance of the AMPLICOR CMV Test was compared to those of the CMV antigenemia assay and the conventional tube culture method. Among 112 plasma specimens from 43 human immunodeficiency virus-infected patients, CMV was detected in 20 (18%) of the specimens by the AMPLICOR CMV Test, 21 (19%) of the specimens by the CMV antigenemia assay, and 10 (9%) of the specimens by culture. In CSF specimens from AIDS patients, CMV was detected in 10 of 58 (17%) specimens tested by the AMPLICOR CMV Test, 5 of 28 (18%) specimens tested by the antigen assay, and none of the 25 specimens tested by culture. While the performance of the AMPLICOR CMV Test in this study was comparable to that of the CMV antigen assay, processing of specimens by the AMPLICOR CMV Test was much simpler than that by the antigen assay; in addition, the antigen assay requires greater than 105 leukocytes from blood or 1 ml of CSF to perform the assay. Our study suggested that the AMPLICOR CMV Test could provide a rapid and sensitive assay for the detection of CMV in plasma and CSF specimens.

show abstract

“…It is a microwell plate assay designed to detect CMV DNA in an ELISA-like colorimetric format following nucleic acid amplification. Preliminary evaluation shows concordance of the results of the AMPLICOR CMV Test with the antigenemia assay (200). The COBAS AMPLICOR CMV Monitor (Roche Molecular Systems) is a fully automated system intended for PCR amplification, detection, and quantitation of CMV in clinical samples (96,218).…”

Section: Pcr Amplificationmentioning

confidence: 95%

“…In a noncompetitive quantitative PCR approach, an internal standard is used that has the same primer binding sites as the target nucleic acid but differs in the intervening sequences used for detection of the amplified product (151,200). The internal standard is added at a known copy number; the target and internal standard are coamplified and detected with probes that have different binding sites.…”

Section: Pcr Amplificationmentioning

confidence: 99%

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients

2000

View full text Add to dashboard Cite

SUMMARY In the past three decades since the inception of human organ transplantation, cytomegalovirus (CMV) has gained increasing clinical import because it is a common pathogen in the immunocompromised transplant recipient. Patients may suffer from severe manifestations of this infection along with the threat of potential fatality. Additionally, the dynamic evolution of immunosuppressive and antiviral agents has brought forth changes in the natural history of CMV infection and disease. Transplant physicians now face the daunting task of recognizing and managing the changing spectrum of CMV infection and its consequences in the organ recipient. For the microbiology laboratory, the emphasis has been geared toward the development of more sophisticated detection assays, including methods to detect emerging antiviral resistance. The discovery of novel antiviral chemotherapy is an important theme of clinical research. Investigations have also focused on preventative measures for CMV disease in the solid-organ transplant population. In all, while much has been achieved in the overall management of CMV infection, the current understanding of CMV pathogenesis and therapy still leaves much to be learned before success can be claimed.

show abstract

Evaluation of the AMPLICOR CMV test for direct detection of cytomegalovirus in plasma specimens

Cited by 34 publications

References 11 publications

Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients

Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients

Detection of Cytomegalovirus in Plasma and Cerebrospinal Fluid Specimens from Human Immunodeficiency Virus-Infected Patients by the AMPLICOR CMV Test

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients

Contact Info

Product

Resources

About